東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Targeting Her2-Positive Breast Cance...

Rainey, Magdalena A.

Linked to FindBook

Google Book

Amazon

博客來

Targeting Her2-Positive Breast Cancer Metabolism Through Dietary and Pharmacological Interventions to Improve Therapeutic Efficacy.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Targeting Her2-Positive Breast Cancer Metabolism Through Dietary and Pharmacological Interventions to Improve Therapeutic Efficacy./
Author:	Rainey, Magdalena A.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
Description:	74 p.
Notes:	Source: Masters Abstracts International, Volume: 80-12.
Contained By:	Masters Abstracts International80-12.
Subject:	Pharmacology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13858921
ISBN:	9781392203224

Targeting Her2-Positive Breast Cancer Metabolism Through Dietary and Pharmacological Interventions to Improve Therapeutic Efficacy.
Rainey, Magdalena A.

Targeting Her2-Positive Breast Cancer Metabolism Through Dietary and Pharmacological Interventions to Improve Therapeutic Efficacy. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 74 p.

Source: Masters Abstracts International, Volume: 80-12.

Thesis (M.S.)--The University of North Carolina at Chapel Hill, 2019.

This item must not be sold to any third party vendors.

HER2-positive breast cancers (HER2+ BC) are an aggressive subset characterized by therapeutic resistance in ∼40-60% of patients. We hypothesized that modulating energy-responsive pathways through either dietary restriction or pharmacological metabolic reprogramming interventions (MRI) would increase the efficacy of HER2-directed therapies trastuzumab and lapatinib. Dietary restriction was modeled in vitro and the efficacy of lapatinib was increased under serum-restricted conditions. This effect was recapitulated with MRIs and we determined that inhibition of IGF1R/insulin receptor and mTORC1 increased the antiproliferative effects of lapatinib. Ongoing work is investigating the impact of intermittent fasting regimens on therapeutic efficacy in vivo by restricting the dietary intake of mice with HER2+ BC for 48 hours coinciding with the administration of trastuzumab or lapatinib. We conclude that inhibition of metabolic pathways implicated in HER2+ BC drug resistance through intermittent fasting regimens and pharmacological MRIs has the potential to increase the efficacy of HER2-directed therapies.

ISBN: 9781392203224Subjects--Topical Terms:

634543
Pharmacology.

Targeting Her2-Positive Breast Cancer Metabolism Through Dietary and Pharmacological Interventions to Improve Therapeutic Efficacy.
LDR:02321nmm a2200373 4500 001 2207289
005 20190916101815.5
008 201008s2019 ||||||||||||||||| ||eng d
020 $a 9781392203224
035 $a (MiAaPQ)AAI13858921
035 $a (MiAaPQ)unc:18564
035 $a AAI13858921
040 $a MiAaPQ $c MiAaPQ
100 1 $a Rainey, Magdalena A. $3 3434262
245 1 0 $a Targeting Her2-Positive Breast Cancer Metabolism Through Dietary and Pharmacological Interventions to Improve Therapeutic Efficacy.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 74 p.
500 $a Source: Masters Abstracts International, Volume: 80-12.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Hursting, Stephen D.
502 $a Thesis (M.S.)--The University of North Carolina at Chapel Hill, 2019.
506 $a This item must not be sold to any third party vendors.
520 $a HER2-positive breast cancers (HER2+ BC) are an aggressive subset characterized by therapeutic resistance in ∼40-60% of patients. We hypothesized that modulating energy-responsive pathways through either dietary restriction or pharmacological metabolic reprogramming interventions (MRI) would increase the efficacy of HER2-directed therapies trastuzumab and lapatinib. Dietary restriction was modeled in vitro and the efficacy of lapatinib was increased under serum-restricted conditions. This effect was recapitulated with MRIs and we determined that inhibition of IGF1R/insulin receptor and mTORC1 increased the antiproliferative effects of lapatinib. Ongoing work is investigating the impact of intermittent fasting regimens on therapeutic efficacy in vivo by restricting the dietary intake of mice with HER2+ BC for 48 hours coinciding with the administration of trastuzumab or lapatinib. We conclude that inhibition of metabolic pathways implicated in HER2+ BC drug resistance through intermittent fasting regimens and pharmacological MRIs has the potential to increase the efficacy of HER2-directed therapies.
590 $a School code: 0153.
650 4 $a Pharmacology. $3 634543
650 4 $a Biochemistry. $3 518028
650 4 $a Nutrition. $3 517777
650 4 $a Public health. $3 534748
650 4 $a Physiology. $3 518431
650 4 $a Oncology. $3 751006
690 $a 0419
690 $a 0487
690 $a 0570
690 $a 0573
690 $a 0719
690 $a 0992
710 2 $a The University of North Carolina at Chapel Hill. $b Nutrition. $3 1020239
773 0 $t Masters Abstracts International $g 80-12.
790 $a 0153
791 $a M.S.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13858921